|
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
|
|
Around The Net
You are reading news provided by a variety of web sources.
Drug Pipeline
| Drug Name | Type Of Drug | FDA Status | Drug Phase |
| JZP-6 |
Other
| Pending Decision | Phase 3 |
Events
FDA Decision:
FDA decision
(relates to the drug JZP-6)
Add New Event
In order to write a comment you must first login.
Login or Register (for free!)
Add Event
Important Links
No links found.
Add New Link
In order to write a comment you must first login.
Login or Register (for free!)
Add Link
|
JAZZ
$9.71
9/3/2010 4:00:00 PM
Sponsors
|